Eagle Pharma’s drug to treat genetic condition gets U.S. approval

(Reuters) – Eagle Pharmaceuticals Inc said the U.S. Food and Drug Administration approved its drug to treat an inherited life-threatening condition called malignant hyperthermia (MH). The drug, Ryanodex, along with supportive measures, is indicated for the treatment of MH, a severe reaction to inhaled anesthetics or the muscle relaxant succinylcholine used during surgery. Eagle Pharmaceuticals is also testing Ryanodex for use in exertional heatstroke.